Following U.S. Stocks were among the “Top Losers” during Friday’s trade: Goodrich Petroleum Corporation (NYSE:GDP), Newmont Mining Corp (NYSE:NEM), Darling Ingredients Inc (NYSE:DAR), Biocept Inc (NASDAQ:BIOC)
Their insights are depicted underneath:
Goodrich Petroleum Corporation (NYSE:GDP) shares dwindled -8.00%, and closed at $3.45.
According to PRNewswire, the board of directors of Goodrich Petroleum Corp. (GDP), has declared a quarterly cash dividend of $0.6719 per share on its 5.375% Series B Cumulative Convertible Preferred Stock, with dividends to be paid on March 16, 2015 to stockholders of record as of March 2, 2015.
In addition, the Board has also declared a quarterly cash dividend of $0.625 per depositary share on its 10.00% Series C Cumulative Preferred Stock, and a quarterly cash dividend of $0.609375 per depositary share on its 9.75% Series D Cumulative Preferred Stock to be paid on March 16, 2015 to stockholders of record as of March 13, 2015.
Goodrich Petroleum Corporation is an independent oil and natural gas exploration and production corporation whose ordinary stock is listed on the New York Stock Exchange under the symbol GDP.
Newmont Mining Corp (NYSE:NEM) declined -7.91%, and closed at $23.30.
According to BUSINESS WIRE, on February 19, Newmont Mining Corporation (NEM), stated gold reserves of 82.2 million ounces and copper reserves of 7.9 billion pounds for 2014.
Notable gold reserve additions for the year comprise 0.7 million ounces at Tanami, 0.2 million ounces at Long Canyon and 0.4 million equity ounces at Merian. The Carlin trend continues to show promising upside, as the Carlin Portals and Leeville collectively added 0.7 million ounces. Overall gold reserve grades were unchanged from the preceding year; however, combined project reserve additions were at a grade that exceeded our portfolio’s average. Gold resource additions1 comprise 1.0 million ounces from Tanami, 1.1 million ounces from Carlin Portals and Leeville, 0.9 million ounces from Apensu Underground, and 0.6 million ounces from Long Canyon.
Newmont stated 82.2 million ounces of attributable gold reserves, 26.7 million ounces of attributable Measured and Indicated gold resources and 16 million ounces attributable Inferred gold resources. Attributable gold reserves were reduced by a net 6.2 million ounces or 7% from the preceding year. Of this reduction, 2.5 million ounces or nearly 40% is due to asset divestitures. Depletion of 5.5 million ounces was partially offset by additions of 3.3 million ounces.
Attributable gold resources were reduced by 1.2 million ounces or 3% from the preceding year. New additions of 5.7 million ounces were offset by conversions of 3.3 million ounces, revisions due to mine plan changes of 2.6 million ounces and divestments of 1.1 million ounces. Not including divestments, attributable gold resources were essentially flat year over year. Gold reserves and resources were calculated at $1,300 per ounce, and $1,400 per ounce, respectively, unchanged from 2013.
Newmont also stated 7.9 billion pounds of attributable copper reserves, 7.3 billion pounds of attributable Measured and Indicated copper resources and 1.7 billion pounds attributable Inferred copper resources. Copper reserves were unchanged from 2013 except for depletion and minor positive revisions, while copper resources were reduced from 2013 primarily due to revisions due to mine plan changes at Phoenix. Copper reserves and resources were calculated at $3.00 per pound, and $3.50 per pound, respectively, unchanged from 2013.\
Attributable Proven and Probable silver reserves for 2014 were 144 million ounces. Attributable Measured and Indicated silver resources for 2014 were 47 million ounces, with additional Inferred silver resources of 19 million ounces. Silver reserves and resources were calculated using prices of $20.00 and $25.00 per ounce, respectively.
Newmont Mining Corporation operates in the mining industry. It primarily attains, develops, explores for, and produces gold, copper, and silver deposits.
Darling Ingredients Inc (NYSE:DAR) dipped -7.87%, and closed at $ 14.76, hitting new 52-week low of $14.58.
According to PRNewswire, Darling Ingredients Inc. (DAR), stated financial results for the fourth quarter and fiscal year ended January 3, 2015.
Net sales for the fourth quarter of 2014 rose to $1.0 billion, contrast with $447.9 million in the same period of 2013, attributable to newly attained operations in first quarter of 2014. Operating revenue in the fourth quarter of 2014 was $39.7 million, contrast with $18.5 million for the same period of 2013.
Fourth quarter 2014 net revenue attributable to Darling was $69.9 million, or $0.42 per diluted share, contrast with net revenue of $22.5 million, or $0.18 per diluted share, in the fourth quarter of 2013. For the fourth quarter of fiscal 2014, the Corporation generated Adjusted EBITDA of $108.7 million, as contrast to $50.2 million in the same period in 2013. The raise was primarily attributable to the inclusion of the blender’s tax credit from the DGD Joint Venture and our newly attained operations. On a Pro Forma Adjusted EBITDA basis, the Corporation would have generated $111.1 million in the fourth quarter 2014, as contrast to a Pro Forma Adjusted EBITDA of $64.4 million in the same period in 2013.
Darling Ingredients Inc. is the world’s largest publicly-traded developer and producer of sustainable natural ingredients from edible and inedible bio-nutrients, creating a wide range of ingredients and customized specialty solutions for customers in the pharmaceutical, food, pet food, feed, technical, fuel, bioenergy and fertilizer industries.
Biocept Inc (NASDAQ:BIOC) dropped -7.74%, and closed at $3.10.
According to GLOBE NEWSWIRE, Biocept, Inc. (BIOC), a molecular oncology diagnostics corporation specializing in Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) biomarker analysis, recently declared that Jason Poole, Ph.D. has joined the Corporation as Senior Director, Molecular Assay Development.
Dr. Poole brings extensive molecular diagnostic development experience to Biocept. Formerly, Dr. Poole was Director, R&D at Trovagene. He has also worked with EMD Millipore in addition to Nanogen, Inc. Dr. Poole has an extensive clinical assay development background, counting noteworthy experience in Next Generation Sequencing, quantitative PCR and in-vitro cell analysis.
“I am very happy to have Jason as part of the Biocept team. He has broad experience in clinical molecular diagnostic development and importantly, has practiced a great deal of success using cell free tumor DNA as a sample target. This experience fits very well with the planned expansion of Biocept’s molecular biomarker product offerings using our SelectorTM technology together with Next Generation Sequencing platforms to further personalize cancer treatments and monitor disease progression using ctDNA,” said Lyle Arnold, Ph.D., Senior Vice President, R&D and Chief Scientific Officer.
Dr. Poole holds a doctorate in Cancer Genetics from the University of Illinois at Chicago. He was a post-doctoral fellow at the University of California, Irvine, where he developed diagnostic assays for inborn errors of metabolism and other human metabolic diseases.
Biocept, Inc., headquartered in San Diego, Calif., is a commercial-stage oncology diagnostics corporation focused on providing information on patients’ tumors to physicians using its proprietary technology platform to assist improve individual patient treatment. Biocept has developed proprietary technology platforms for capture and analysis of circulating tumor DNA, both in circulating tumor cells (CTCs) and in plasma (cell free tumor DNA).
